Animal studies on obesity The most compelling data comes from studies in diet-induced obese mice
Disposition : Structure: Acylated peptide with a fatty diacid moiety extends half-life via albumin binding Half-life: ~6 days supports once-weekly dosing Administration: Subcutaneous injection Clinical Data Highlights : Weight Loss: Up to 24.2% body weight reduction in phase 2 trials, highest recorded among incretin-based therapies Glycemic Control: HbA1c reductions of 2.02.5% in type 2 diabetes patients Lipid Profile: Significant drops in triglycerides, LDL-C, and liver fat content Insulin Sensitivity: Improved HOMA-IR and fasting insulin levels Energy Expenditure: Increased basal metabolic rate and fat oxidation via glucagon receptor activation For a full breakdown of Retatrutide clinical trials and results you can click the link
If morning dosing doesn't fit your schedule, inject at least 3-4 hours after your last meal and 45 minutes before your next
This was confirmed across multiple studies measuring serum IGF-1 at baseline and throughout treatment
Clinical trials confirmed no effect on serum IGF-1 levels, no negative effect on carbohydrate metabolism, and no anti-AOD-9604 antibodies detected in any participants
When comparing methylcobalamin vs cyanocobalamin, cyanocobalamin is widely used as it is generally considered more cost-effective
